- INOVIQ (IIQ) confirms positive results during its testing for ovarian cancer
- The company wrapped up its Ovarian Cancer 97 study, which was undertaken by the Centre for Clinical Research at The University of Queensland
- The study confirmed the utility of EXO-NET for extracellular vesicle (EV) biomarker discovery, with over 90 per cent accuracy for the detection of early-stage ovarian cancer
- The company says its next steps will include an analytical validation study to establish equivalence of the EV-based ovarian cancer test in plasma compared to serum from the same cohort of patients
- INOVIQ climbs 13.9 per cent, trading at 69.5 cents at 3:06 pm AEDT
INOVIQ (IIQ) has confirmed positive results during its testing for ovarian cancer.
The company has now wrapped up its Ovarian Cancer 97 study, which was undertaken by the Centre for Clinical Research at The University of Queensland.
The study confirmed the utility of EXO-NET for extracellular vesicle (EV) biomarker discovery and generation of a multivariate index assay, with over 90 per cent accuracy for the detection of early-stage ovarian cancer.
Data from 97 plasma samples, including ovarian cancer, benign and healthy controls, identified highly significant differences between the EV biomarker content of ovarian cancer and control samples.
Data showed a multivariate algorithm using selected EV biomarkers achieved 92 per cent accuracy for detection of early-stage ovarian cancers in an independent sample set.
“The OC97 study is the first milestone achieved in the collaboration with The University of Queensland to develop a world-first EV ovarian cancer screening test,” CEO Dr Leearne Hinch said.
“OC97 has successfully established that EXO-NET effectively isolates EV biomarkers from plasma and has identified additional informative biomarkers for inclusion in UQ’s OCRF7 ovarian cancer test.
The multivariate index assay (MIA) showed over 90 per cent accuracy for detection of early stage ovarian cancers, when the cancer can be more effectively treated and help save women’s lives.”
The company said its next steps will include an analytical validation study to establish equivalence of the EV-based ovarian cancer test in plasma compared to serum from the same cohort of patients.
INOVIQ climbed 13.9 per cent, trading at 69.5 cents at 3:06 pm AEDT.